Canada biotech news - the latest news from Labiotech.eu

Five biotech companies making a name for themselves in Vancouver

Willow Shah-Neville — Fri, 30 Jun 2023 11:02:30 +0000

British Columbia has become a major hub of biotech innovation within the last decade or more, and the popular coastal city of Vancouver is the center of the life sciences sector in the province. In this article we take a look at five of the top biotech companies located in the city. According to a […]

The post Five biotech companies making a name for themselves in Vancouver appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Med-Life Discoveries to start rare pediatric disease trial

Jim Cornall — Fri, 09 Jun 2023 10:00:00 +0000

Med-Life Discoveries, LP (MLD) is a Canadian biopharmaceutical company dedicated to advancing a therapy to reduce symptoms for a devastating pediatric rare disease, Rhizomelic chondrodysplasia punctata (RCDP), which causes significant physical and neurological delays in children who inherit it. Med-Life Discoveries has received a no objection letter (NOL) from Health Canada to begin a phase […]

The post Med-Life Discoveries to start rare pediatric disease trial appeared first on Labiotech.eu.

$5.5M funding for Oncopole to tackle cancer

Jim Cornall — Tue, 06 Jun 2023 09:49:05 +0000

Oncopole, Fonds de recherche du Québec – Santé (FRQS) cancer division in Canada, has received major investments that boost its public-private partnership model dedicated to the fight against cancer. Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada. Oncopole, FRQS cancer division, is the result of […]

The post $5.5M funding for Oncopole to tackle cancer appeared first on Labiotech.eu.

Recursion boosts drug discovery with Cyclica and Valence acquisitions

Jim Cornall — Tue, 09 May 2023 10:00:00 +0000

Recursion has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica, for $40 million, and Valence, for $47.5 million. Chris Gibson, co-founder and CEO of Salt Lake City headquartered Recursion, said: “Recursion has pioneered the massive, parallel generation of -omics data with machine learning in order to map and navigate biology […]

The post Recursion boosts drug discovery with Cyclica and Valence acquisitions appeared first on Labiotech.eu.

Inspire Biotherapeutics launches to target lung diseases through gene therapy

Jim Cornall — Thu, 16 Mar 2023 10:03:36 +0000

Inspire Biotherapeutics Inc., an emerging Canadian biotech company with a mission to create gene therapies for monogenic and acquired diseases of the lung, is set to move its novel lung tropic AAV gene therapy into clinical validation. The AAVenger platform has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types […]

The post Inspire Biotherapeutics launches to target lung diseases through gene therapy appeared first on Labiotech.eu.

IMV presents positive lymphoma trial results

Jim Cornall — Tue, 14 Feb 2023 11:57:53 +0000

IMV Inc. has announced positive preliminary data from its VITALIZE phase 2B trial. The study is evaluating IMV Inc. lead DPX product, maveropepimut-S (MVP-S), in combination with pembrolizumab, in patients with relapsed, refractory diffuse large B cell lymphoma (r/r DLBCL). IMV Inc. is a biopharmaceutical company developing a portfolio of immune-educating therapies based on its […]

The post IMV presents positive lymphoma trial results appeared first on Labiotech.eu.

Next-generation small molecules hold promise for immunotherapy

External Contributor — Wed, 01 Feb 2023 08:39:48 +0000

By Ian B. Walters, chief executive officer and chairman, Portage Biotech In recent years, PD-1/PD-L1 checkpoint antibody therapies have revolutionized the immuno-oncology landscape and offered cancer patients the hope for a long term treatment and cure of their disease. While these treatments have shown great promise in reversing T-cell exhaustion, many patients still have limited […]

The post Next-generation small molecules hold promise for immunotherapy appeared first on Labiotech.eu.

Watch: Sernova’s Cell Pouch System tackles diabetes

Jim Cornall — Tue, 20 Dec 2022 19:40:15 +0000

Sernova Corp. is a Canadian-based clinical-stage biotechnology company that is developing its Cell Pouch System. This is a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a […]

The post Watch: Sernova’s Cell Pouch System tackles diabetes appeared first on Labiotech.eu.

Providence Therapeutics’ mRNA rabies vaccine hits milestone

Jim Cornall — Fri, 16 Dec 2022 11:09:15 +0000

Providence Therapeutics Holdings Inc. says its new mRNA vaccine program for rabies post-exposure prophylaxis has achieved a preclinical proof-of-concept milestone. The candidate was developed in partnership with Everest Medicines utilizing Providence’s clinically validated mRNA technology platform. “We are pleased to demonstrate that Providence’s mRNA technology supports development of additional products that fight a number of […]

The post Providence Therapeutics’ mRNA rabies vaccine hits milestone appeared first on Labiotech.eu.

ExPLoRNA Therapeutics receives mRNA technology funding

Jim Cornall — Wed, 07 Dec 2022 14:37:48 +0000

ExPLoRNA Therapeutics, a Polish biotech company working on mRNA vaccines and therapeutics, has received funding from the Bill & Melinda Gates Foundation to further develop its mRNA technology. ExPLoRNA specializes in novel cap analogs, the starting part of mRNA crucial for enabling successful production of the encoded protein. ExPLoRNA’s technology increases protein production beyond the […]

The post ExPLoRNA Therapeutics receives mRNA technology funding appeared first on Labiotech.eu.

Five apps powering the future of at-home HIV tests

Jonathan Smith — Thu, 01 Dec 2022 14:27:26 +0000

The smartphone revolution is providing a promising tool to combat the human immunodeficiency virus (HIV) epidemic. We’ve listed five HIV test apps in development that could help people carry out at-home HIV tests and prevent the spread of the infection. The COVID-19 pandemic in the last two years has demonstrated how vital rapid diagnostic tests […]

The post Five apps powering the future of at-home HIV tests appeared first on Labiotech.eu.

Novavax’ COVID-19 vaccine gets expanded authorization for booster in adults

Liza Laws — Fri, 18 Nov 2022 17:13:54 +0000

Novavax, Inc., a U.S-based biotechnology company announced today (November 18) that Health Canada has granted expanded authorization for Covid-19 vaccine Nuvaxovid. The vaccine NVX-CoV2373 for active immunization to prevent the disease caused by severe acute respiratory syndrome (SARS-CoV-2) as a homologous booster in adults aged 18 and older. “Canadians now have access to our […]

The post Novavax’ COVID-19 vaccine gets expanded authorization for booster in adults appeared first on Labiotech.eu.

The hottest private biotech companies in Canada

Jonathan Smith — Thu, 17 Nov 2022 16:12:01 +0000

Canada is well known for biotech innovations, with expertise in genomics, cell therapies and liquid biopsy. Here is a list of private healthcare biotech companies that have attracted big cash in Canada in the past two years. Canada has one of the top 10 biggest economies in the world. The developed country boasts rich forests, […]

The post The hottest private biotech companies in Canada appeared first on Labiotech.eu.

Could DNA nanotransporters treat cancer?

Jim Cornall — Wed, 02 Nov 2022 10:46:56 +0000

A team of Canadian researchers from Université de Montréal has designed and validated a new class of drug transporters made of DNA 20,000 times smaller than a human hair. The DNA nanotransporters could improve how cancers and other diseases are treated. Reported in a new study in Nature Communications, the molecular transporters can be chemically […]

The post Could DNA nanotransporters treat cancer? appeared first on Labiotech.eu.

Delayed release tablets to treat ulcerative colitis launched in Canada

Liza Laws — Tue, 25 Oct 2022 05:00:00 +0000

With Canada having one of the highest incidences of ulcerative colitis in the world, the recent launch of Tillotts Pharma AG’s Octasa 800 mg will be well-received. Tillotts is part of the Japanese Zeria Group, and announced Octasa (mesalazine) delayed-release tablets, as first-line treatment for moderately active ulcerative colitis (UC) in Canada. The launch, the […]

The post Delayed release tablets to treat ulcerative colitis launched in Canada appeared first on Labiotech.eu.

Distributor of Curcugen and Ginfort receives dual natural product licenses

Liza Laws — Tue, 25 Oct 2022 04:30:00 +0000

Two Health Canada natural product licenses have been achieved by DolCas Biotech LLC and have been found safe, effective and high quality. The products are its concentrated turmeric extract, Curcugen, and the other for Ginfort, a powerful ginger extract in powdered format. Produced by Olene Life Sciences, the two ingredient brands are research-backed for clinical […]

The post Distributor of Curcugen and Ginfort receives dual natural product licenses appeared first on Labiotech.eu.

Mass production of lutetium for targeted cancer therapeutics following collaboration

Liza Laws — Mon, 24 Oct 2022 15:17:34 +0000

An international collaboration marking the start of commercial production of lutetium-177 was celebrated in Munich between Canada-based Bruce Power, Isogen and Isotope Technologies Munich (ITM). The announcement was celebrated along with representatives of the partnership organizations during a trade mission with Vic Fedeli, Ontario’s Minister of Economic Development, Job Creation and Trade. This milestone was […]

The post Mass production of lutetium for targeted cancer therapeutics following collaboration appeared first on Labiotech.eu.

Sunshine Biopharma acquires Nora Pharma

Jim Cornall — Thu, 20 Oct 2022 19:33:05 +0000

Sunshine Biopharma Inc, a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. Nora Pharma is now a wholly owned subsidiary of Sunshine Biopharma Inc. The addition of Nora Pharma allows Sunshine Biopharma to expand […]

The post Sunshine Biopharma acquires Nora Pharma appeared first on Labiotech.eu.

Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market

Jim Cornall — Thu, 20 Oct 2022 10:47:00 +0000

Alvotech and the JAMP Pharma Group have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech. The companies have added two biosimilar candidates from Alvotech’s pipeline: AVT16, a proposed biosimilar to an undisclosed immunology product and AVT33, a proposed biosimilar to an undisclosed oncology product. “We are very pleased to be expanding […]

The post Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market appeared first on Labiotech.eu.

Report says 20% of global cancer deaths could be avoided

Jim Cornall — Wed, 19 Oct 2022 08:58:17 +0000

A new study by members of the Bloomberg New Economy International Cancer Coalition says at least 1.5 million deaths from cancer could be avoided each year. This is 20% of the annual global deaths resulting from cancer. The study says this could happen if international regulations around patient trials were more standardized and people placed […]

The post Report says 20% of global cancer deaths could be avoided appeared first on Labiotech.eu.